Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2017 16:05 ET | Source: Neuralstem, Inc.

Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder

GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...
February 28, 2017 07:03 ET | Source: Neuralstem, Inc.

Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology

-NSI-189 Showed Durable Functional Recovery in a Rodent Model of Ischemic Stroke- -NSI-189 Promoted Synaptic Remodeling After Stroke- GERMANTOWN, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Neuralstem,...
February 22, 2017 07:03 ET | Source: Neuralstem, Inc.

Neuralstem Announces Issuance of U.S. Patent Covering NSI-189

GERMANTOWN, Md., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
December 12, 2016 07:38 ET | Source: Neuralstem, Inc.

Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.

GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...